These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 33294467)

  • 1. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
    Joshi M; Ansell SM
    J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
    J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of immune checkpoint inhibition in malignant lymphoma.
    Hude I; Sasse S; Engert A; Bröckelmann PJ
    Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
    Shaver KA; Croom-Perez TJ; Copik AJ
    Front Immunol; 2021; 12():679117. PubMed ID: 33995422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
    Xia Y; Medeiros LJ; Young KH
    Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
    Barroso-Sousa R; Tolaney SM
    Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
    Merryman RW; Houot R; Armand P; Jacobson C
    Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
    Tun AM; Ansell SM
    Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving role of lenalidomide in non-Hodgkin lymphoma.
    Galanina N; Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series).
    Sukari A; Kukreja G; Nagasaka M; Shukairy MK; Yoo G; Lin HS; Hotaling J; Kim H
    Oral Oncol; 2020 Oct; 109():104744. PubMed ID: 32402656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulators in Lymphoma.
    Anagnostou T; Ansell SM
    Curr Treat Options Oncol; 2020 Mar; 21(4):28. PubMed ID: 32193838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint inhibition in lymphoma.
    Shah GL; Moskowitz CH
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):45-55. PubMed ID: 29741505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
    Zhang N; Wei L; Ye M; Kang C; You H
    Front Immunol; 2020; 11():592612. PubMed ID: 33329578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting indolent non-Hodgkin lymphoma.
    Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
    Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.
    Jin KT; Wang SB; Ying XJ; Lan HR; Lv JQ; Zhang LH; Motallebnezhad M; Mou XZ
    Immunol Lett; 2020 May; 221():61-71. PubMed ID: 32097671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
    Dermime S; Merhi M; Merghoub T
    Front Immunol; 2021; 12():781872. PubMed ID: 34745152
    [No Abstract]   [Full Text] [Related]  

  • 19. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma.
    Zeng FL; Chen JF
    Technol Cancer Res Treat; 2021; 20():15330338211039952. PubMed ID: 34528830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.
    Hu J; Xiao Q; Dong M; Guo D; Wu X; Wang B
    Front Immunol; 2020; 11():593219. PubMed ID: 33329583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.